PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 14, Issue 5, Pages 597-608
Publisher
Informa Healthcare
Online
2013-03-09
DOI
10.1517/14656566.2013.778828
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
- (2012) A. T. Shaw et al. ANNALS OF ONCOLOGY
- Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement,ALKsignal copy number, and response to crizotinib therapy inALKfluorescence in situ hybridization-positive nonsmall cell lung cancer
- (2012) D. Ross Camidge et al. CANCER
- Association ofEGFRmutation orALKrearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma
- (2012) Shengxiang Ren et al. CANCER
- Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing
- (2012) Pengyuan Liu et al. CARCINOGENESIS
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- (2012) Marcin Imielinski et al. CELL
- The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5' and 3' Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers
- (2012) R. Wang et al. CLINICAL CANCER RESEARCH
- Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer
- (2012) K. D. Davies et al. CLINICAL CANCER RESEARCH
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development
- (2012) Giorgio Scagliotti et al. EUROPEAN JOURNAL OF CANCER
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK
- (2012) Jong-Mu Sun et al. Journal of Thoracic Oncology
- Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell Lung Cancer
- (2012) Nir Peled et al. Journal of Thoracic Oncology
- Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent
- (2012) Chris M.J. Conklin et al. Journal of Thoracic Oncology
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- (2012) D Ross Camidge et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients
- (2012) Heae Surng Park et al. LUNG CANCER
- Treating ALK-positive lung cancer—early successes and future challenges
- (2012) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Genetic insight and therapeutic targets in squamous-cell lung cancer
- (2012) M L Sos et al. ONCOGENE
- Crizotinib for the Treatment of ALK -Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
- (2012) Sai-Hong Ignatius Ou et al. ONCOLOGIST
- KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only
- (2012) Yuki Togashi et al. PLoS One
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
- (2012) Erik Thunnissen et al. VIRCHOWS ARCHIV
- A Screening Method for the ALK Fusion Gene in NSCLC
- (2012) Yoshiko Murakami et al. Frontiers in Oncology
- Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas
- (2011) Akihiko Yoshida et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A novelKIF5B-ALKvariant in nonsmall cell lung cancer
- (2011) Daisy Wing-Sze Wong et al. CANCER
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- Clinical Significance of Thyroid Transcription Factor-1 in Advanced Lung Adenocarcinoma Under Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment
- (2011) Kuei-Pin Chung et al. CHEST
- New Strategies for Treatment of ALK-Rearranged Non-Small Cell Lung Cancers
- (2011) T. Sasaki et al. CLINICAL CANCER RESEARCH
- Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer
- (2011) Marcello Tiseo et al. Expert Review of Anticancer Therapy
- More Than Just an Oncogene Translocation and a Kinase Inhibitor: Kevin's Story
- (2011) Daniel B. Costa JOURNAL OF CLINICAL ONCOLOGY
- Finding ALK-Positive Lung Cancer: What Are We Really Looking for?
- (2011) D. Ross Camidge et al. Journal of Thoracic Oncology
- Apoptotic Pathway Manipulation
- (2011) D. Ross Camidge et al. Journal of Thoracic Oncology
- Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization
- (2011) Jin Ho Paik et al. Journal of Thoracic Oncology
- Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib
- (2011) Sanjay Popat et al. Journal of Thoracic Oncology
- Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
- (2011) D. Ross Camidge et al. Journal of Thoracic Oncology
- Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study
- (2011) Anne McLeer-Florin et al. Journal of Thoracic Oncology
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models
- (2011) E Normant et al. ONCOGENE
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Co-Activation of Epidermal Growth Factor Receptor and c-MET Defines a Distinct Subset of Lung Adenocarcinomas
- (2010) Daisuke Matsubara et al. AMERICAN JOURNAL OF PATHOLOGY
- ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
- (2010) David E. Gerber et al. CANCER CELL
- A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
- (2010) M. Mino-Kenudson et al. CLINICAL CANCER RESEARCH
- Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
- (2010) D. R. Camidge et al. CLINICAL CANCER RESEARCH
- Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation
- (2010) Yao-Wen Kuo et al. Journal of Thoracic Oncology
- The mutation spectrum revealed by paired genome sequences from a lung cancer patient
- (2010) William Lee et al. NATURE
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS
- (2009) Daisy Wing-Sze Wong et al. CANCER
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset
- (2009) Kentaro Inamura et al. MODERN PATHOLOGY
- Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers
- (2009) E. Lin et al. MOLECULAR CANCER RESEARCH
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
- (2009) G. Scagliotti et al. ONCOLOGIST
- Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
- (2008) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
- (2008) J. P. Koivunen et al. CLINICAL CANCER RESEARCH
- Identification of ALK as a major familial neuroblastoma predisposition gene
- (2008) Yaël P. Mossé et al. NATURE
- Activating mutations in ALK provide a therapeutic target in neuroblastoma
- (2008) Rani E. George et al. NATURE
- Oncogenic mutations of ALK kinase in neuroblastoma
- (2008) Yuyan Chen et al. NATURE
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
- (2008) Isabelle Janoueix-Lerosey et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now